Jefferies Raises INNOVENT BIO Target Price to HK$105, Maintains "Buy" Rating

Stock News

Sep 02

Jefferies released a research report stating that INNOVENT BIO (01801) is expanding its commercialization capabilities beyond the oncology field, covering diversified channels. The company's self-developed PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 will independently initiate a global Phase III clinical trial for squamous non-small cell lung cancer. The firm believes it shows potential for melanoma (mucosal and acral types) at low doses (1mg/kg). The firm maintains a "buy" rating on the stock with a target price raised to HK$105.

The firm estimates that INNOVENT BIO's sales for fiscal years 2025 and 2026 will be RMB 500 million and RMB 1.2 billion respectively, with a monthly average cost of RMB 1,200, comparable to semaglutide and 30% cheaper than tirzepatide. The new drug application for IBI112 (IL-23p19) for psoriasis is under review, with approval in China expected in the second half of 2025.

Additionally, the firm has raised its revenue forecasts for INNOVENT BIO for fiscal years 2025 to 2027 to RMB 13 billion, RMB 15 billion, and RMB 20 billion respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1113330513"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1113330513\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1113330513?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-02 17:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113330513","market":"sg","top_or_hot":-1,"title":"Jefferies Raises INNOVENT BIO Target Price to HK$105, Maintains \"Buy\" Rating","media":"Stock News","content":"<p>Jefferies released a research report stating that INNOVENT BIO (01801) is expanding its commercialization capabilities beyond the oncology field, covering diversified channels. The company's self-developed PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 will independently initiate a global Phase III clinical trial for squamous non-small cell lung cancer. The firm believes it shows potential for melanoma (mucosal and acral types) at low doses (1mg/kg). The firm maintains a \"buy\" rating on the stock with a target price raised to HK$105.</p>\n<p>The firm estimates that INNOVENT BIO's sales for fiscal years 2025 and 2026 will be RMB 500 million and RMB 1.2 billion respectively, with a monthly average cost of RMB 1,200, comparable to semaglutide and 30% cheaper than tirzepatide. The new drug application for IBI112 (IL-23p19) for psoriasis is under review, with approval in China expected in the second half of 2025.</p>\n<p>Additionally, the firm has raised its revenue forecasts for INNOVENT BIO for fiscal years 2025 to 2027 to RMB 13 billion, RMB 15 billion, and RMB 20 billion respectively.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jefferies Raises INNOVENT BIO Target Price to HK$105, Maintains \"Buy\" Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJefferies Raises INNOVENT BIO Target Price to HK$105, Maintains \"Buy\" Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-02 17:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jefferies released a research report stating that INNOVENT BIO (01801) is expanding its commercialization capabilities beyond the oncology field, covering diversified channels. The company's self-developed PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 will independently initiate a global Phase III clinical trial for squamous non-small cell lung cancer. The firm believes it shows potential for melanoma (mucosal and acral types) at low doses (1mg/kg). The firm maintains a \"buy\" rating on the stock with a target price raised to HK$105.</p>\n<p>The firm estimates that INNOVENT BIO's sales for fiscal years 2025 and 2026 will be RMB 500 million and RMB 1.2 billion respectively, with a monthly average cost of RMB 1,200, comparable to semaglutide and 30% cheaper than tirzepatide. The new drug application for IBI112 (IL-23p19) for psoriasis is under review, with approval in China expected in the second half of 2025.</p>\n<p>Additionally, the firm has raised its revenue forecasts for INNOVENT BIO for fiscal years 2025 to 2027 to RMB 13 billion, RMB 15 billion, and RMB 20 billion respectively.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2097828474.EUR","symbol_name":"AZ EQUITY CHINA \"A\" (EUR) ACC A","start_time":0,"source_url":"","article_id":"1113330513","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113330513","pubTimestamp":1756803664,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Jefferies released a research report stating that INNOVENT BIO (01801) is expanding its commercialization capabilities beyond the oncology field, covering diversified channels. The company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","BK1583":"高瓴概念","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","BK1589":"北水核心资产","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","01801":"信达生物","BK1161":"生物科技","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC"},"translate_title":"富瑞上调信达生物目标价至105港元维持“买入”评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"Jefferies released a research report stating that INNOVENT BIO (01801) is expanding its commercialization capabilities beyond the oncology field, covering diversified channels. The company's self-developed PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 will independently initiate a global Phase III clinical trial for squamous non-small cell lung cancer. The firm believes it shows potential for melanoma (mucosal and acral types) at low doses (1mg/kg). The firm maintains a \"buy\" rating on the stock with a target price raised to HK$105.\nThe firm estimates that INNOVENT BIO's sales for fiscal years 2025 and 2026 will be RMB 500 million and RMB 1.2 billion respectively, with a monthly average cost of RMB 1,200, comparable to semaglutide and 30% cheaper than tirzepatide. The new drug application for IBI112 (IL-23p19) for psoriasis is under review, with approval in China expected in the second half of 2025.\nAdditionally, the firm has raised its revenue forecasts for INNOVENT BIO for fiscal years 2025 to 2027 to RMB 13 billion, RMB 15 billion, and RMB 20 billion respectively.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}